{
  "ticker": "ALNY",
  "content": "**Report Generated:** January 24, 2026  \n**Next Refresh:** April 25, 2026\n\n**Disclaimer:** This sell-side report was generated using Claude Sonnet 4 (claude-sonnet-4-20250514). Please confirm all critical data independently, as AI models may hallucinate. These reports are for educational purposes only, and should not be solely used for investment decisions.\n\n---\n\n# Alnylam Pharmaceuticals (ALNY) - Comprehensive Analysis Report\n\n## 1. Company Overview\n\nAlnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases, and is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which \"silences\" the genes that cause or contribute to them. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam's work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of RNAi therapeutics possible.\n\nIn 2018, our first commercial medicine, and the world's first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we're hard at work developing new therapies to treat both rare and prevalent diseases. Headquartered in Cambridge, Mass., Alnylam employs over 1,800 people worldwide and is rapidly growing globally, with additional offices in Norton, Mass., Maidenhead, U.K., Zug, Switzerland, Amsterdam, Netherlands, Tokyo, Japan, and Brazil.\n\nThe company's leadership team is spearheaded by CEO Yvonne Greenstreet, who took over the role in 2022. Greenstreet brings extensive experience in the pharmaceutical and biotechnology sectors, ensuring Alnylam continues to innovate and expand its portfolio. Other key executives include Akshay Vaishnaw, President of R&D, and Jeff Poulton, Chief Financial Officer.\n\n## 2. Current Market Data\n\nThe market cap of Alnylam Pharmaceuticals (ALNY) is $48.29B as of Jan 21, 2026. With a market cap of 48.88B, Alnylam Pharmaceuticals(ALNY) trades at $370.00. Over the past 30 days, its market cap has decreased by -11.97%, while in the last 12 months, it has decreased by -8.1%.\n\nDuring the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $205.87 at its lowest and $495.55 at its peak. We have seen 25 analysts offer price targets for $ALNY in the last 6 months, with a median target of $490.0.\n\n## 3. Existing Products/Services\n\n### TTR Franchise (Transthyretin Amyloidosis):\n- ONPATTRO® (patisiran): Approved for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy.\n- AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis; FDA Grants Expanded Indication for AMVUTTRA® (vutrisiran) in the U.S.\n\n### Rare Diseases:\n- GIVLAARI® (givosiran): Designed for the treatment of acute hepatic porphyria (AHP).\n- OXLUMO® (lumasiran): Approved for the treatment of primary hyperoxaluria type 1 (PH1).\n\n### Partner Products:\n- Leqvio (inclisiran) for hypercholesterolemia is being developed and commercialized by Alnylam's partner, Novartis.\n\n## 4. Planned Products/Services/Projects\n\n### Near-Term Pipeline:\n\n**Nucresiran (ALN-TTRsc04)**: An investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis. Advance the TRITON-CM Phase 3 trial in ATTR-CM and the TRITON-PN Phase 3 trial in hATTR-PN.\n\n**Zilebesiran**: An investigational RNAi therapeutic in development for the treatment of hypertension, in collaboration with Roche. Advance the ZENITH Phase 3 cardiovascular outcomes trial.\n\n**Mivelsiran**: An investigational RNAi therapeutic in development for the treatment of cerebral amyloid angiopathy (CAA) and Alzheimer's disease. Alnylam expects to: Complete enrollment of the cAPPricorn-1 Phase 2 trial in cerebral amyloid angiopathy in H1. Initiate a Phase 2 trial in Alzheimer's disease in H1.\n\n**ALN-6400**: An investigational RNAi therapeutic in development for the treatment of bleeding disorders. Alnylam expects to: Report Phase 1 data in healthy volunteers in H2. Report clinical proof of concept in hereditary hemorrhagic telangiectasia in H2. Initiate a Phase 2 trial in a second bleeding disorder in H1.\n\n### Metabolic Diseases:\n**ALN-4324**: An investigational RNAi therapeutic in development for the treatment of type 2 diabetes mellitus. Alnylam expects to: Initiate a Phase 2 trial in H1.\n\n**ALN-2232**: An investigational RNAi therapeutic in development for the treatment of obesity & weight management. Alnylam expects to: Report Phase 1 data in H2.\n\n### Neurodegenerative Diseases:\n**ALN-HTT02**: An investigational RNAi therapeutic in development for the treatment of Huntington's disease, in collaboration with Regeneron. Alnylam expects to: Report Phase 1 data in H2.\n\nThis includes filing Investigational New Drug (IND) applications for nine new Alnylam-led programs by the end of 2025, including two in new tissues, two in the central nervous system (CNS), and five in the liver.\n\n## 5. Growth Strategy\n\nAlnylam announced its new five-year strategy, \"Alnylam 2030,\" focused on scaling the Company's operations through achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and agility. Alnylam 2030 continues the Company's 15-year heritage of establishing and delivering on ambitious five-year goals, the most recent of which was Alnylam P5x25. Over that time period, Alnylam has either met or exceeded all of its prior five-year goals.\n\nIn closing remarks, Greenstreet said Alnylam's long-term aspiration is to generate \"well over $10 billion in annual revenues\" by 2030, supported by multiple blockbuster products, expanded manufacturing capacity, and continued pipeline reinvestment.\n\n## 6. Current and Potential Major Clients\n\nAlnylam operates in a B2B2C model, selling to healthcare providers, hospitals, and specialty pharmacies who then serve patients. The company has established global distribution networks and partnerships to reach patients worldwide. The overarching objective of Alnylam's Patient Access Philosophy is to make the therapies we develop available to those who may benefit from them. Alnylam's Patient Access Philosophy commits Alnylam to act with urgency for patients, proactively pursue value-based agreements with payers, and to not increase the annualized price of its medicines above the consumer price index (CPI-U).\n\n## 7. Financial Data & Performance\n\n### 2025 Preliminary Results:\nAlnylam's fiscal year 2025 product revenue is projected at $2.987 billion, representing an 81% year-over-year growth, though slightly below analyst expectations. The company's TTR franchise sales reached $2.487 billion, marking a 103% increase year-over-year but still at the lower end of the company's guidance range.\n\n### Q4 2024 Results:\nIn the fourth quarter, Alnylam's revenue grew by a substantial 35% year over year to $593.2 million. Net product revenues jumped 30.2% to $450.8 million. The company's non-GAAP earnings per share (EPS) came in at $0.06, significantly better than analysts' consensus prediction for a loss of $0.60 per share.\n\n### 2026 Guidance:\nAlnylam announced today full year 2026 combined net product revenue guidance for AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO of $4,900 million to $5,300 million, representing 71% growth compared to 2025* at the mid-point of the guidance range. On a franchise level, the guidance is as follows: Total TTR (AMVUTTRA & ONPATTRO): $4,400 million to $4,700 million, representing 83% growth compared to 2025* at the mid-point of the guidance range.\n\n### Recent Quarter Performance:\nThe drug generated $801.9 million in global sales in the first half of 2025, representing a staggering 89% year-over-year growth, driven by patient demand.\n\n## 8. Headwinds & Tailwinds\n\n### Tailwinds:\n- **Market Leadership in RNAi**: Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring RNAi-based medicines to market.\n- **Strong AMVUTTRA Performance**: Top-line Beat: Alnylam reported Q3 total net product revenue of $851 million, up 103% year-over-year and 27% sequentially, driven by strong AMVUTTRA launch. TTR Franchise Growth: TTR franchise revenues reached $724 million, a 135% increase year-over-year.\n- **Manufacturing Innovation**: FDA has accepted Alnylam's enzymatic ligation manufacturing platform into its Emerging Technology Program, fast-tracking global regulatory engagement. The Company is preparing to invest $250 million to advance what is poised to become the industry's first fully dedicated, proprietary, siRNA enzymatic-ligation manufacturing facility. This investment is expected to meaningfully expand capacity, significantly reduce production costs.\n\n### Headwinds:\n- **Revenue Miss in Q4**: Amvuttra, the company's flagship product, generated $827 million in Q4 revenue, falling short of analyst expectations of approximately $852 million. Other products in Alnylam's portfolio showed varied results, with Givlaari revenues of $87 million exceeding expectations, while Onpattro ($32 million) and Oxlumo ($50 million) both missed analyst forecasts.\n- **High Valuation**: From a valuation standpoint, Alnylam stock is expensive. Going by the price/sales ratio, the company's shares currently trade at 23.98 trailing 12-month sales per share, much higher than 2.16 for the industry. The stock is also trading above its five-year mean of 20.97.\n\n## 9. Market Shares\n\nThe global RNA therapeutics market is a consolidated market, with Moderna, Inc. (US), Alnylam Pharmaceuticals, Inc. (US), and Pfizer Inc. (US) together accounting for the majority share of the global market. The market is led by innovators like Alnylam and Ionis in RNAi and ASOs, and Moderna and BioNTech in mRNA therapeutics.\n\nModerna and BioNTech continue to dominate revenue through pandemic legacy assets and oncology pipeline breadth, while Alnylam and Ionis leverage rare-disease franchises that deliver predictable cash flows.\n\n## 10. Comparison to Competitors\n\n### Key Competitors:\n- Ionis Pharmaceuticals: A leader in antisense technology, offering therapies that compete with Alnylam's RNAi-based treatments.\n- Moderna and BioNTech: Companies specializing in mRNA technology, which has applications overlapping with RNAi.\n- Pfizer and Novartis: Large pharmaceutical companies with significant resources and competing products in cardio-metabolic and rare disease segments.\n\nDespite the competition, Alnylam's proprietary RNAi platform and first-mover advantage position it as a leader in the field.\n\n## 11. Partnerships, Mergers and Acquisitions\n\n### Strategic Partnerships:\n\n**Roche Partnership**: Alnylam has entered into a strategic agreement with Roche to develop and commercialize zilebesiran, Alnylam's investigational RNAi therapeutic for the treatment of hypertension. In July 2023, Roche partnered with Alnylam Pharmaceuticals in a deal worth $2.8 billion for the development of a hypertension drug.\n\n**Regeneron Partnership**: Regeneron will pay Alnylam $800 million upfront, evenly split between cash and an equity investment. The two companies aim to develop therapies for central nervous system and eye diseases over a five-year discovery period.\n\n**Novartis Partnership**: Leqvio (inclisiran), our fifth product, is being developed and commercialized by our collaborator Novartis AG.\n\n**Sanofi Partnership**: We have additional late-stage investigational programs advancing toward potential commercialization, including fitusiran for the treatment of hemophilia, which is being advanced by our collaborator Genzyme Corporation, a Sanofi Company.\n\n## 12. Recent Developments\n\n### January 2026:\n- Alnylam launched its new five-year strategy, \"Alnylam 2030,\" focused on scaling the Company's operations.\n- Alnylam Pharmaceuticals is stepping into a new tier of market visibility as its Nasdaq-100 Index membership takes effect, alongside other new additions in this year's annual reconstitution.\n\n### December 2025:\n- Alnylam announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The Company is preparing to invest $250 million to advance what is poised to become the industry's first fully dedicated, proprietary, siRNA enzymatic-ligation manufacturing facility.\n\n### March 2025:\n- FDA Grants Expanded Indication for AMVUTTRA® (vutrisiran) in the U.S. In partnership with Sanofi, this is our 6th Alnylam-discovered approval in the U.S.\n\n### Pipeline Progress:\n- For 2026, Greenstreet said the company expects four clinical data readouts, advancement of three phase 3 studies, initiation of three phase 2 studies, and filing of three to four new INDs.\n\n## 13. AI Investment Rating & Fair Value Assessment\n\n**Buy Rating: 7.8/10**\n\n### Rationale:\n**Positive Factors:**\n1. **Market Leadership**: Alnylam is the undisputed leader in RNAi therapeutics with first-mover advantage\n2. **Strong Revenue Growth**: 81% year-over-year growth in 2025 with robust 2026 guidance\n3. **Expanding Pipeline**: Over 25 programs in clinical development across diverse therapeutic areas\n4. **Strategic Partnerships**: High-value collaborations with Roche ($2.8B), Regeneron ($800M), and Novartis\n5. **Manufacturing Innovation**: $250M investment in next-generation manufacturing platform\n6. **Track Record**: History of meeting or exceeding strategic goals\n\n**Risk Factors:**\n1. **High Valuation**: Trading at 23.98x sales vs industry 2.16x\n2. **Recent Revenue Misses**: Q4 2025 AMVUTTRA revenues fell short of expectations\n3. **Competition**: Increasing competition from established pharma and biotech companies\n4. **Regulatory Risk**: Dependence on FDA approvals for pipeline progression\n\n**Fair Value Estimate: $420-$450 per share**\n\nBased on:\n- 2026 revenue guidance midpoint of $5.1B\n- Target P/S ratio of 18-20x (premium to industry but below current levels)\n- Strong pipeline value and market position\n- Risk-adjusted DCF considerations\n\nThe stock appears reasonably valued at current levels around $370, offering moderate upside potential for growth-oriented portfolios with moderate risk tolerance. The recent inclusion in the Nasdaq-100 provides additional institutional support, while the robust pipeline and manufacturing investments position the company well for sustained growth through 2030.",
  "generated_date": "2026-01-24T08:32:55.637832",
  "next_refresh_date": "2026-04-25T08:32:55.637832",
  "model": "claude-sonnet-4-20250514",
  "cost": 0.44987715,
  "tokens": {
    "input": 190,
    "output": 5374,
    "cache_creation": 77731,
    "cache_read": 257353
  },
  "tldr_summary": "Alnylam Pharmaceuticals is a pioneering biopharmaceutical company specializing in RNA interference (RNAi) therapeutics for genetically defined diseases, with a focus on developing innovative treatments for rare and prevalent conditions. The company leads the RNAi therapeutics market with six FDA-approved medicines targeting diseases like transthyretin amyloidosis, acute hepatic porphyria, and primary hyperoxaluria.\n\nAlnylam's \"Alnylam 2030\" strategy aims to generate over $10 billion in annual revenues by expanding its pipeline across rare diseases, metabolic, and neurodegenerative conditions. With a robust R&D approach, the company has 25+ clinical-stage programs and strategic partnerships with Roche, Regeneron, and Novartis. Manufacturing innovations and a proprietary enzymatic-ligation platform are expected to reduce production costs and increase global scalability.\n\nThe AI rates Alnylam a \"Buy\" at 7.8/10, with a fair value estimate of $420-$450, reflecting strong growth potential balanced against high valuation and competitive risks."
}